Atossa Therapeutics (ATOS) Cash from Investing Activities (2011 - 2025)
Atossa Therapeutics (ATOS) posted quarterly Cash from Investing Activities of -$7000.0 for Q4 2025, little changed quarter-over-quarter from -$7000.0 in Q3 2025.
Atossa Therapeutics (ATOS) Cash from Investing Activities (2011 - 2025) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Cash from Investing Activities for 13 consecutive years, with -$7000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Investing Activities changed N/A year-over-year to -$7000.0; the TTM figure through Mar 2026 stood at -$14000.0 (up 36.36% YoY), while the FY2025 annual figure was -$23000.0, down 21.05% from the prior year.
- Cash from Investing Activities held at -$7000.0 in Q4 2025 per ATOS's latest filing, from -$7000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$1000.0 in Q3 2023 and bottomed at -$2.7 million in Q3 2022.
- Historically, Cash from Investing Activities has averaged -$399333.3 across 5 years, with a median of -$9000.0 in 2021.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 29966.67% — and 2023, when it soared 99.96%.
- Atossa Therapeutics' Cash from Investing Activities stood at -$9000.0 in 2021, then tumbled by 22211.11% to -$2.0 million in 2022, then jumped by 99.95% to -$1000.0 in 2023, then plunged by 900.0% to -$10000.0 in 2024, then increased by 30.0% to -$7000.0 in 2025.
- Business Quant data shows ATOS's Cash from Investing Activities at -$7000.0 in Q4 2025, -$7000.0 in Q3 2025, and -$9000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Sep 30, 2025 | -7,000.00 |
| Sep 30, 2025 | -7,000.00 |
| Mar 31, 2025 | -9,000.00 |
| Mar 31, 2025 | -9,000.00 |
| Sep 30, 2024 | -10,000.00 |
| Sep 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -3,000.00 |
| Jun 30, 2024 | -3,000.00 |
| Mar 31, 2024 | -6,000.00 |
| Mar 31, 2024 | -6,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -13,000.00 |
| Jun 30, 2023 | -13,000.00 |
| Dec 31, 2022 | -2.01 Mn |
| Dec 31, 2022 | -2.01 Mn |
| Sep 30, 2022 | -2.71 Mn |
| Sep 30, 2022 | -2.71 Mn |